4//SEC Filing
Karpf David B 4
Accession 0001126234-22-000008
CIK 0001126234other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 4:35 PM ET
Size
8.0 KB
Accession
0001126234-22-000008
Insider Transaction Report
Form 4
LUMOS PHARMA, INC.(LUMO)
Karpf David B
Chief Medical Officer
Transactions
- Award
Common Stock
2022-02-01$10.02/sh+400$4,008→ 7,900 total - Award
Stock Option (Right to Buy)
2022-02-01+5,000→ 5,000 totalExercise: $10.02Exp: 2032-01-31→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]Represents shares issued as restricted stock units ("RSUs") under the Issuer's 2009 Equity Incentive Plan, as amended, (the "Plan") that were received as an award, for no consideration. The RSUs vest in a series of four successive annual installments beginning on February 1, 2023, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
- [F2]Includes 7,500 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of four successive annual installments beginning on September 1, 2022, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
- [F3]Grant to the Reporting Person of a stock option under the Plan. The option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on March 1, 2022, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the date of grant.
Documents
Issuer
LUMOS PHARMA, INC.
CIK 0001126234
Entity typeother
Related Parties
1- filerCIK 0001622067
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 4:35 PM ET
- Size
- 8.0 KB